22
Participants
Start Date
June 30, 2002
Primary Completion Date
March 31, 2014
Study Completion Date
January 31, 2020
Busulfan, Fludarabine, ATG, TLI
Busulfan 0.8 mg/kg/dose intravenous (IV) Days -8 and -7 Fludarabine 35 mg/m2 IV Days -6 through -2 Antithymocyte globulin (ATG) 30 mg/kg IV Days -2 and -1 Total lymphoid radiation 300 cGy
Busulfan, Cyclophosphamide, ATG, GCSF
Busulfan 0.8 mg/kg/dose intravenous (IV) Days -9 through -6 Cyclophosphamide 50 mg/kg IV Days -5 through -2 ATG 30 mg/kg IV Day -1 GCSF 5 mcg/kg/day IV until ANC \>2500 x 2 days.
Campath, Fludarabine, Cyclophosphamide
Receives Campath-1H 0.2 mg/kg Days -10 through -6, Fludarabine 35 mg/m2 intravenous (IV) Days -6 through -2, total body irradiation (TBI) 300 cGy Day -1.
Total Body Irradiation
300 cGY Day -1
Stem cell infusion
Given Day 0
Masonic Cancer Center, University of Minnesota, Minneapolis
National Marrow Donor Program
OTHER
Masonic Cancer Center, University of Minnesota
OTHER